REGENXBIO(RGNX) - 2023 Q4 - Annual Results

EXHIBIT 99.1 • ABBV-RGX-314 Subretinal Delivery for the Treatment of Wet AMD o Enrollment is on track in ATMOSPHERE ® and ASCENT™ pivotal trials and these trials are expected to support global regulatory submissions with the U.S. Food and Drug Administration and the European Medicines Agency in late 2025 through the first half of 2026. • ABBV-RGX-314 Suprachoroidal Delivery for Treatment of Wet AMD o REGENXBIO expects to share new program and data updates for the Phase II AAVIATE trial in mid-2024. o In Jan ...